Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness... Autor Yena Gan, Fenghao Shi, Fenghao Shi, He Zhu, He Zhu, Sheng Han, Sheng Han, Duoduo Li

Získat plný text

Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study Autor Fenghao Shi, Fenghao Shi, Zixuan He, Zixuan He, Lin Wang, Hang Su, Hang Su, Sheng Han, Sheng Han

Získat plný text

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China Autor Fenghao Shi, Fenghao Shi, Zixuan He, Zixuan He, Hang Su, Hang Su, Lin Wang, Sheng Han, Sheng Han

Získat plný text

Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and s... Autor Yena Gan, Fenghao Shi, Fenghao Shi, He Zhu, He Zhu, Huangqianyu Li, Huangqianyu Li, Sheng Han, Sheng Han, Duoduo Li

Získat plný text

Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis Autor Yu Xie, Hua Xing, Zihao Wang, Hongbin Yi, Fenghao Shi, Liping Kuai, Dongyan Xu

Získat plný text

Cost-effectiveness of universal genetic screening for familial hypercholesterolemia in young adults aged 18–40 years in China Autor Rui Meng, Fenghao Shi, Baoming Zhang, Chao Li, Jinyan Wang, Lingqin Song, Lei Zhang, Mingwang Shen

Získat plný text